Ignite Creation Date:
2025-12-24 @ 11:50 PM
Ignite Modification Date:
2025-12-31 @ 3:02 PM
Study NCT ID:
NCT01237951
Status:
COMPLETED
Last Update Posted:
2020-05-05
First Post:
2010-11-08
Is NOT Gene Therapy:
True
Has Adverse Events:
True
Brief Title:
High-Dose Gemcitabine, Busulfan and Melphalan With Hematopoietic-Cell Support for Patients With Poor-Risk Myeloma
Sponsor:
M.D. Anderson Cancer Center
Organization:
Key Dates - Follows AllAPIJSON File Order
Start Date:
2010-11-08
Start Date Type:
ACTUAL
Primary Completion Date:
2017-09-20
Primary Completion Date Type:
ACTUAL
Completion Date:
2017-09-20
Completion Date Type:
ACTUAL
First Submit Date:
2010-11-08
First Submit QC Date:
None
Study First Post Date:
2010-11-10
Study First Post Date Type:
ESTIMATED
Results First Submit Date:
2018-06-25
Results First Submit QC Date:
None
Results First Post Date:
2020-05-05
Results First Post Date Type:
ACTUAL
Results First Post QC Date:
None
Results First Post QC Date Type:
None
Disp First Submit Date:
None
Disp First Submit QC Date:
None
Disp First Post Date:
None
Disp First Post Date Type:
None
Last Update Submit Date:
2020-04-23
Last Update Post Date:
2020-05-05
Last Update Post Date Type:
ACTUAL